Aimmune Therapeutics was founded in 2011 and is headquartered in Brisbane, US
Aimmune Therapeutics Office Locations
Aimmune Therapeutics has an office in Brisbane
Brisbane, US (HQ)
300 8000 Marina Blvd
Aimmune Therapeutics Data and Metrics
Aimmune Therapeutics Financial Metrics
$, USD
Net income (FY, 2016) | (80.8 m) |
EBIT (FY, 2016) | (81.5 b) |
Market capitalization (22-Jun-2017) | 1 b |
Closing share price (22-Jun-2017) | 19.2 |
Cash (31-Dec-2016) | 124 m |
Aimmune Therapeutics's current market capitalization is $1 b.
| $, USD | FY, 2015 | FY, 2016 |
|---|---|---|
R&D expense | 19.8 m | 54.6 b |
General and administrative expense | 16.2 m | 26.9 b |
Operating expense total | 36 m | 81.5 b |
EBIT | (36 m) | (81.5 b) |
Interest expense | (36 k) | |
Interest income | 217 k | |
Pre tax profit | (35.8 m) | (80.8 b) |
Net Income | (35.8 m) | (80.8 m) |
| $, USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 76.7 m | 124 m |
Inventories | 5.6 m | 2.7 m |
Current Assets | 197.5 m | 251.7 m |
PP&E | 2.7 m | 10.4 m |
Total Assets | 212.4 m | 298.8 m |
Accounts Payable | 1.9 m | 1.4 m |
Current Liabilities | 5.1 m | 11.5 m |
Additional Paid-in Capital | 259.7 m | 420.2 m |
Retained Earnings | (53.3 m) | (134.2 m) |
Total Equity | 206.3 m | 286 m |
Financial Leverage | 1 x | 1 x |
| $, USD | FY, 2015 | FY, 2016 |
|---|---|---|
Net Income | (35.8 m) | (80.8 m) |
Depreciation and Amortization | 115 k | 534 k |
Inventories | 4 m | |
Accounts Payable | 1.1 m | (994 k) |
Cash From Operating Activities | (35.7 m) | (56.6 m) |
Purchases of PP&E | (1.7 m) | (7.7 m) |
Cash From Investing Activities | (125.2 m) | (43.9 m) |
Cash From Financing Activities | 235.3 m | 147.8 m |
| Y, 2016 | |
|---|---|
Financial Leverage | 1 x |
